Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “HYPNOTICS”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 109 records · Page 6Linked to original sources
PubMed1986

Expectancy versus absorption in the prediction of hypnotic responding.

The Absorption Scale, a measure of imaginative involvement, was administered to 64 subjects in the context of a hypnosis experiment and to an additional 64 subjects in a context unrelated to hypnosis. Expectancies of responding to hypnotic suggestions were assessed both before trance induction and after trance induction but before administration of hypnotic test suggestions. Hypnotic depth was assessed on the Long Stanford Scale (LSS) before the administration of test suggestions, and on the Inventory of Hypnotic Depth (IHD) after the hypnosis session. Absorption was correlated with hypnotic responsivity and expectancy, but only when assesed in the hypnotic context. Completing the Absorption Scale in a hypnotic context appeared to affect hypnotic responsiveness by altering subjects' expectancies. Only postinduction expectancies were uniquely predictive of response to hypnotic test suggestions, and all variables except the LSS were predictive of IHD scores. Results of path analysis supported the hypothesis that trance inductions alter expectancies for responding to hypnotic suggestions and that these altered expectancies determine subsequent hypnotic behavior.

Adult↗
PubMed1984

Changes in hypnotic usage in residential homes for the elderly: a longitudinal study.

The use of hypnotic drugs in 25 local authority homes for the elderly was recorded on a 1-day point prevalence study following a 6-mth monitoring programme involving all new admissions. From a total population of 1114 residents 390 (35%) were taking hypnotics on the night of the survey, showing a slight increase from similar surveys carried out in 1980 and 1981. The proportion of residents receiving hypnotics within each home varied from 0.0 to 61.8%. Correlation with levels of usage in the previous surveys was low, suggesting that pattern of hypnotic usage may change considerably over time within individual homes. Of the 156 residents who were admitted as permanent residents during the 6-mth period preceding the survey, 56 (35.9%) had been taking hypnotics on admission. Both the results of the drug monitoring programme and the survey show an association between hypnotic usage and source of admission: residents admitted from hospital being more likely to be taking sleeping tablets. A considerable change was found in the type of hypnotic currently prescribed with an increased preference being shown for short half-life hypnotics. A higher proportion of residents also were prescribed lower doses of hypnotics than previously, suggesting an increased awareness of the risks associated with hypnotic use in the elderly.

Aged↗
PubMed1991

Insomnia and use of hypnotics: study of a French population.

A cross-sectional study of insomnia and hypnotic use was performed in a sample of the French population. The quota method was used to select the sample of 1,003 subjects, with less than 3% substitution. Subjects were 15 years old and older and were representative of the French population based on gender, age, marital status and living environment. Subjects were asked questions relevant to the complaint of insomnia and hypnotic use and filled out questionnaires measuring anxiety and depression. The complaint of insomnia is common, even in the 15-24-year-old group. Overall, more women than men were afflicted. The largest group of insomniac subjects, and the group who most often used hypnotics "frequently and chronically", were women 45 years and older. Men presented a sharp increase in hypnotic use after 65 years of age. Ten percent of the entire sample used hypnotics, 8% for more than 6 months and 6.17% on a chronic and frequent basis. Retired and unemployed elderly were also chronic and frequent hypnotic users: aging and social isolation correlate with chronic and frequent hypnotic usage. Higher scores on anxiety and depression scales correlate with more frequent complaints of nocturnal sleep disturbances. Young individuals are a significant complainer group but use hypnotics rarely. A rural environment was associated, overall, with fewer insomnia complaints, but environment had much less impact on complaints and hypnotic use in the elderly than in other age groups. One may question whether, in the French population, hypnotic prescription and intake are not responses to a social rather than a medical problem.

Adolescent↗
PubMed1994

Perturbation of ion channel conductance alters the hypnotic response to the alpha 2-adrenergic agonist dexmedetomidine in the locus coeruleus of the rat.

BACKGROUND: The alpha 2-adrenergic agonists are members of a novel class of hypnotic-anesthetic agents that selectively bind to alpha 2 adrenoceptors in the locus coeruleus (LC) to initiate their pharmacologic action. The postreceptor molecular mechanism of the hypnotic action of alpha 2-adrenergic agonists remains unknown. In this study we addressed the role of conductance through a variety of calcium and potassium ion channels in the hypnotic action of dexmedetomidine in the LC of the rat. METHODS: Cannulas were inserted stereotactically into the LC of halothane-anesthetized rats (n = 318). After at least 48 h, rats were tested for loss of righting reflex in response to administration of the alpha 2-adrenergic agonist dexmedetomidine at a hypnotic (7.0 micrograms LC) or subhypnotic (3.5 micrograms LC) dose. To establish the mediating role of various species of calcium and potassium ion channels in the hypnotic response, rats were pretreated with the following drugs before the administration of dexmedetomidine LC:S(+)202791 (L-type calcium-channel activator), nifedipine and R(-)202791 (L-type calcium-channel blocker), SNX 111 (N-type calcium-channel blocker), SNX 230 (P-type calcium-channel blocker), quinine (calcium-activated and voltage-gated potassium-channel blocker), charybdotoxin (calcium-activated potassium-channel blocker), dendrotoxin (voltage-gated potassium-channel blocker), or glybenclamide (adenosine triphosphate-sensitive potassium-channel blocker). The drugs were used in doses not causing behavioral effects that could have confounded the interpretation of loss of righting reflex. RESULTS: SNX 230 and the dihydropyridines nifedipine and R(-)202791 produced loss of righting reflex in the presence of a subhypnotic dose of dexmedetomidine. The hypnotic-enhancing effects of the dihydropyridines could be blocked with S(+)202791, which also diminished loss of righting reflex in response to dexmedetomidine 7.0 micrograms LC. Quinine, dendrotoxin, and charybdotoxin each attenuated the hypnotic response to dexmedetomidine 7.0 micrograms LC. The hypnotic response to dexmedetomidine was not significantly altered by SNX 111 or glybenclamide. CONCLUSIONS: Inhibition of ion conductance through L- or P-type calcium channels and facilitation of conductance through voltage-gated or calcium-activated potassium channels may be involved in the mechanism of hypnotic action of alpha 2-adrenergic agonists. These changes in ion conductance were capable of producing membrane hyperpolarization and decreasing neuronal excitability. There was no evidence for the involvement of adenosine triphosphate-sensitive potassium channels or N-type calcium channels in the hypnotic response to dexmedetomidine.

Adrenergic alpha-Agonists↗
PubMed2002

High resolution EEG indicators of pain responses in relation to hypnotic susceptibility and suggestion.

In this report we use a dense array (129 electrodes) EEG procedure to examine the effects of hypnotic susceptibility and hypnotic suggestions on electrocortical and self-report measures of painful stimuli. Self-report and event-related potential measures of six high and six low hypnotic susceptible individuals in response to pain were examined during an initial baseline condition and following a standard hypnotic induction under suggestions to either increase (hyperalgesia) or decrease (hypoalgesia) the painful stimulation. Our results show that high and low hypnotically susceptible individuals: (1) show few self-report or psychophysiological differences in response to baseline pain stimuli; (2) report differential pain experiences depending on hypnotic suggestions and (3) display differential psychophysiological indicators following an hypnotic induction with a suggestion of hypoalgesia. Overall, the findings suggest that hypnotic suggestions with high susceptible individuals modulate the later components of the evoked potential in a global manner and point up the importance of using both high and low hypnotically susceptible individuals preceding and following an hypnotic induction.

Adult↗
PubMed1998

Use of hypnotics among patients in geriatric institutions.

A survey of hypnotic use in geriatric institutions outside hospitals was performed in the county of Hordaland, Norway. The data were obtained from the cardex system in 67 institutions and represented administration of hypnotics to the patients on 3 separate days within a week. About 24% of 2802 patients in the institutions used hypnotics. The number of patients treated with hypnotics, the doses administrated and the time of administration were similar for weekends and workdays. About 98% of the hypnotics were used as scheduled, and 41% of the doses administrated were higher than the recommended lowest dose for elderly patients. Long-acting benzodiazepines constituted about 62% of the hypnotics. A significantly higher proportion of patients in old age homes used hypnotics compared to patients in nursing homes (30.7% versus 22.9%, respectively, p < 0.01). Furthermore, higher doses, administration later in the evening and use of additional hypnotics were more common in old age homes compared to nursing homes. The results indicate a need for frequent reevaluation of prescribing of hypnotics in geriatric institutions.

Aged↗
PubMed1987

N-substituted oxopyrimidines and nucleosides: structure-activity relationship for hypnotic activity as central nervous system depressant.

N3-Benzyluridine (3-(phenylmethyl)-1-beta-D-ribofuranosyluracil) (1f) and its related compounds were synthesized and evaluated for hypnotic activity as central depressants. The primary structural modification has been carried out at the N3 position of the pyrimidine ring in uridine. N3-Benzyl-substituted uridine exhibited hypnotic activity as well as pentobarbital (PB) induced sleep effect on mice when administered by intracerebroventricular (icv) injection. From this result, the secondary modification was performed, namely, converting the benzyl group into a benzyl analogous group. These compounds also showed hypnotic activity, but their intensities were varied. Thirdly, changing the sugar moiety was investigated; however, it was found to be necessary for hypnotic activity. In general, introduction of benzyl analogous groups at the N3 position of uridine increased the hypnotic activity, and modification of the sugar moiety decreased the activity. Intravenous (iv) administration failed to indicate hypnotic activity in most of the compounds tested. However, modified sugars such as 2',3',5'-tri-O-methyl or -acetyl derivatives of 1f elicited hypnotic activity by iv injection. The majority of compounds were found to show potentiation of the PB-induced sleep, and their effects were in parallel with the hypnotic activity. The result clearly indicates that the benzyl group and beta-D-ribofuranosyl, at the N3 and N1 positions, respectively, are necessary for hypnotic activity. The critical portion of the chemical structure for both effects appears to be the uridine moiety.

Animals↗
PubMed2002

The prevalence and clinical course of sedative-hypnotic abuse and dependence in a large cohort.

Relatively little is known about the prevalence and clinical characteristics of dependence on sedative-hypnotics, and almost nothing has been published regarding abuse. This report relates information on Diagnostic and Statistical Manual of the American Psychiatric Association (DSM-IIIR) sedative-hypnotic use disorders among subjects from the Collaborative Study on the Genetics of Alcoholism (COGA). A standardized interview was used to generate data on 407 men and women in Group 1 with sedative-hypnotic dependence (4.4% of the COGA sample), 34 in Group 2 with abuse (0.4%), and 3,426 comparison subjects in Group 3 with alcohol dependence in the absence of a sedative-hypnotic use disorder (36.7%). The remaining COGA subjects (48.5%) were not included as they had neither alcohol nor sedative-hypnotic dependence or abuse. Those with sedative-hypnotic abuse or dependence were more likely to be Caucasian individuals with abuse or dependence on marijuana, cocaine, amphetamines, or opioids. Subjects in Groups 1 and 2 were also more likely to have histories of independent major depressive and panic disorders, as well as substance-induced mood disorders. Those with dependence, compared to abuse, were likely to be women, reported staying intoxicated for a day or more, but noted less abuse of opioids or amphetamines, although Group 2 members also had high rates of difficulties with sedative-hypnotics. These results highlight notable rates of sedative-hypnotic dependence in the COGA families, and indicate that while sedative-hypnotic abuse does occur, and while the clinical course can involve relatively serious problems, it is less common than dependence.

Adult↗
PubMed1992

A hypnotic response to dexmedetomidine, an alpha 2 agonist, is mediated in the locus coeruleus in rats.

Dexmedetomidine, the highly selective alpha 2-adrenergic agonist, produces a dose-dependent hypnotic response in rats through a central mechanism. Because the locus coeruleus (LC) contains pathways involved in the maintenance of vigilance and a high prevalence of alpha 2 adrenoceptors, we investigated the role of this brainstem nucleus in the hypnotic response to dexmedetomidine. The experimental model consisted of chronic, stereotactically cannulated rats (n = 157) in which the hypnotic response to dexmedetomidine was assessed by the duration of the loss of their righting reflex. Correct placement of the cannula was confirmed histologically at necropsy. The hypnotic response to dexmedetomidine 0.3-333.3 micrograms administered into the LC increased in a dose-dependent fashion. Dexmedetomidine 6.6 micrograms injected 2 mm lateral to the LC did not cause the animals to lose their righting response. Atipamezole 0.07 micrograms-12 micrograms, a selective alpha 2-adrenergic antagonist, blocked the hypnotic response to dexmedetomidine 6.6 micrograms when both were administered into the LC. Also, atipamezole 0.7-30 micrograms, administered into the LC, blocked in a dose-dependent manner the hypnotic response to intraperitoneal (ip) dexmedetomidine 50 micrograms.kg-1. Atipamezole injected into the LC did not block the hypnotic response to pentobarbital 40 mg.kg-1 ip. Prazosin, an alpha 1-adrenergic antagonist, 4.2 micrograms into the LC or 1.0 mg.kg-1 ip, did not alter the hypnotic response to dexmedetomidine 6.6 micrograms into the LC. The present data suggest that alpha 2-adrenergic receptors in the LC appear to be a major site for the hypnotic action of dexmedetomidine.(ABSTRACT TRUNCATED AT 250 WORDS)

Adrenergic alpha-Agonists↗
PubMed1995

Sleep quality and the use of benzodiazepine hypnotics in general practice.

The aim of the study was to determine the usage patterns of benzodiazepine hypnotics, the use of other ways of improving sleep and general sleep characteristics in patients prescribed these drugs on a regular basis and in a control group of age- and sex-matched patients not receiving hypnotics. Patients receiving regular benzodiazepine hypnotic prescriptions and a control group matched for age and sex were identified from a general practice computer. They were interviewed in their own homes about their habits relating to sleep, hypnotic use and attitudes to sleep and hypnotics. None of the recommended methods of improving sleep differed significantly in frequency between the two groups or had an effect on sleep parameters. Only daytime napping was found to be slightly more frequent in hypnotic users, but had no apparent effect on self-estimates of sleep duration or latency. The hypnotic users claimed a longer sleep latency and a shorter sleep duration than non-users. More patients who took hypnotics also perceived them to be beneficial and more convenient than other ways of promoting sleep. The recommendation of sleep-promoting methods such as caffeine and alcohol avoidance and regular exercise may not be helpful in patients attempting to avoid hypnotics, as many patients already claim to use such methods.

Adult↗
PubMed1995

Sleep and hypnotics among the elderly in relation to body weight and somatic disease.

OBJECTIVES: To investigate the interrelationship between sleep complaints and hypnotics in relation to general health and somatic diseases. DESIGN: An epidemiological survey conducted by means of a questionnaire. SETTING: The counties of Västerbotten and Norrbotten in northern Sweden. SUBJECTS: All 10,216 members of the Swedish Pensioners' Association. MAIN OUTCOME MEASURES: Sleep disturbances, health, somatic diseases and hypnotic medication. RESULTS: General ill health, cardiovascular diseases, different painful diseases and increased nocturnal voiding frequency were all associated with poor sleep and increased treatment with hypnotics. Hypnotics were used by 13.5% of the men and 22.3% of the women. Of the men aged < 70 years, 7.9% were receiving such treatment, of those aged 70-80 years 14.4% were using hypnotics, and of those aged > or = 80 years 21.8% were taking hypnotics (P < 0.0001). The corresponding frequencies among women were 15.0%, 23.0% and 34.9%, respectively (P < 0.0001). Half of all men and women treated with hypnotics in all age groups reported a good night's sleep. Among these both angina pectoris and cardiac arrhythmia were twice as common as among elderly subjects who experienced poor sleep and were receiving treatment with hypnotics. CONCLUSIONS: Poor health and different somatic diseases are over-represented in elderly persons treated with hypnotics.

Aged↗
PubMed1982

[Insomnia therapy and withdrawal of hypnotics].

The aim of this study is to evaluate the efficiency of a treatment prescribed, in the course of an hospital consultation for sleep pathology, to patients suffering from chronic insomnia not improved by longstanding and sustained medication with hypnotic drugs. The basis of the treatment is a progressive but total withdrawal of hypnotics in so far taken regularly. The withdrawal of hypnotics was prescribed to 79 patients: 33 aged 17 to 39 years (group 1, mean age 30) and 46 aged 40 to 70 years (group 2, mean age 51). 41 showed primary psychophysiological insomnia and 28 showed insomnia associated with psychiatric disorders. In patients of group 1, the average durations were 8 years for insomnia and 3 years for sustained hypnotic use; these durations were 15 and 5 years respectively in patients of group 2. Hypnotic drug withdrawal was achieved without placebos in 3 months in group 1 patients and 5 months in group 2 patients. 65 patients completely stopped the continual use of hypnotics. Subjective improvement of insomnia was reported by 51 of these patients (as well as by 6 patients who were given simultaneous antidepressant therapy). 16 of the 51 improved patients have resorted to hypnotics occasionally (at intervals of 10 days or more). After complete withdrawal, patients went on consulting for various lengths of time: 5 months average for group 1, 14 months average for group 2. This study of a fairly large group of insomniacs shows the frequent ineffectiveness of a sustained use of currently available hypnotics. It also shows that two times out of three the complete stop of sustained hypnotic medication proved beneficial to the patient.

Adolescent↗
PubMed1996

[Recent progress in development of psychotropic drugs (5)--Hypnotics].

Regarding the treatment of insomnia, it is said that a considerable degree of advancement has been made to date in terms of controlling toxicity, preventing the development of tolerance and avoiding addiction, which were often observed when administering barbiturates. Nevertheless, the majority of hypnotics used today, which are benzodiazepines, still retain certain side effects such as hangover effects, development of dependence, rebound insomnia as a withdrawal symptom, muscular atonia resulting in falling down and causing bone fracture, inhibition of respiratory system, negative interaction with alcohol, etc. The current trend of selecting hypnotics is to use short-half-life agents. However, there are yet other problems such as cognitive disorders including amnesia, rebound insomnia and increased anxiety during the daytime. In order to cope with these problems, three new hypnotics have recently been developed. They are non-benzodiazepine derivatives and considered to be safer than the others, because they are supposed to cause less side effects than conventional hypnotics. The pharmacokinetic characteristics of these new hypnotics can be summarized as follows: 1) these hypnotics have selective affinity to benzodiazepine receptor omega-1 subtype although the agent itself does not belong to the benzodiazepine derivative family; 2) the half-life-time in the serum is extremely short, namely 1-2 hours; 3) they increase the level of slow waves (delta-wave) during sleep; 4) they have a lesser effect toward atonic muscle and amnestic thought and behavioral disturbance as compared to conventional hypnotics; and 5) the risks of developing drug tolerance and reciprocal negative effects with alcohol are smaller. Consequently, we can expect that these new hypnotics will bring a certain advantage, especially regarding the avoidance of hypnotics-induced side effects in the course of clinical treatment of insomnia in the future.

Acetamides↗
PubMed2006

Mediation and moderation of psychological pain treatments: response expectancies and hypnotic suggestibility.

The mediator role of response expectancies and the moderator role of hypnotic suggestibility were evaluated in the analogue treatment of pain. Approximately 1,000 participants were assessed for hypnotic suggestibility. Later, as part of a seemingly unrelated experiment, 188 of these individuals were randomly assigned to distraction, cognitive-behavioral package, hypnotic cognitive-behavioral package, hypnotic analgesia suggestion, placebo control, or no-treatment control conditions. Response expectancies partially mediated the effects of treatment on pain. Hypnotic suggestibility moderated treatment and was associated with the relief produced only by the hypnotic interventions. The results suggest that response expectancies are an important mechanism of hypnotic and cognitive-behavioral pain treatments and that hypnotic suggestibility is a trait variable that predicts hypnotic responding across situations, including hypnosis-based pain interventions.

Adolescent↗
PubMed2000

Chronic hypnotic use: deadly risks, doubtful benefit. REVIEW ARTICLE.

In the United States, roughly 2/3 of all hypnotic prescriptions go to chronic users, who have taken hypnotics for an average of 5 years or more. Two large prospective epidemiological studies have shown that reported hypnotic use, especially use 30 times per month, is associated with an excess hazard of death. Indeed, use of hypnotics 30 times per month is associated with a similar mortality hazard to smoking 1-2 packs of cigarettes per day. Moreover, the hypnotic user's wish to improve daytime function is usually unfulfilled. The preponderance of evidence is that hypnotics impair performance, cognition and memory, increase the risk of automobile accidents and falls and promote unfavourable changes in personality. Due to tolerance, the sleep-promoting effects of hypnotics appear to be lost with chronic use. With long-term use, there is little controlled evidence that hypnotics produce benefits of any sort. More study of long-term hypnotic effects by public agencies is needed, but available evidence weighs strongly against long-term prescribing.

Journal Article↗
PubMed1992

The spectral analysis of hypnotic performance with respect to "absorption".

In factor analyses of the hypnosis scales, the essential result is that the items form a continuous, 2-dimensional fan-shaped pattern. This continuum is referred to as the "spectrum of hypnotic performance." "Special analysis" is introduced as an exploratory procedure which makes use of this notion of continuum or spectrum. Spectral analysis consists of a graphical display of the level of latent correlation between a variable and individual hypnotic performances when the latter are arranged according to their position in the spectrum. The spectral analysis of hypnotic performance with respect to absorption is illustrated using data from a sample of 160 Ss. The results indicate that absorption is more strongly related to difficult hypnotic performances than to easy ones. In particular, illustrative item characteristic curves are presented to show that although easy hypnotic performances do not require the processes tapped by individual differences in absorption, a certain level of absorption is necessary to pass difficult hypnotic items. In addition, a high level of absorption may be sufficient in and of itself for difficult hypnotic performances. These results are discussed in light of some speculations by Shor, M. T. Orne, and O'Connell (1962) and Tellegen (1978/1979) concerning the differential contribution of ability components to performance on difficult hypnotic suggestions. The results are also related to a variety of work in social psychological models of hypnotic performance.

Factor Analysis, Statistical↗
PubMed1993

Hypnotic susceptibility and the endogenous eyeblink: a brief communication.

This study investigated the relationship between hypnotic susceptibility, hypnotic state, and the endogenous eyeblink with 36 undergraduates, who were assigned to four independent groups (waking-low, hypnotized-low, waking-high, and hypnotized-high susceptibles) on the basis of combined cutoff scores on both the Creative Imagination Scale and the Stanford Hypnotic Clinical Scale for Adults. The auditory vigilance task required subjects to discriminate between 200 ms and 300 ms tones over a 35-minute period. Hypnotic depth was controlled across trials using the Long Stanford Scale of Hypnotic Depth. As predicted, high-susceptible subjects had a significantly lower blink rate than low-susceptible subjects. The predicted interaction between susceptibility and hypnotic state was also confirmed. High-susceptible subjects showed a significant decrease in blinking for the hypnotized condition, whereas low-susceptible subjects did not. The need for replication with more adequate measures of susceptibility is discussed.

Adult↗
PubMed2004

Hypnotic and tranquillizer use among general practitioners in south-eastern France and its relation to occupational characteristics and prescribing habits.

Previous research suggests that practising physicians are more likely than the general population to use psychotropic drugs. Hypnotic and tranquillizer use in France is among the highest in Europe; most hypnotic and tranquillizer prescriptions are written by general practitioners (GPs). The objective was to compare the hypnotic and tranquillizer use of GPs in private practice in Provence (south-eastern France) with that of the general population and to study factors associated with physicians' hypnotic and tranquillizer use. A cross-sectional telephone survey was carried out with a panel of 600 GPs in Provence. The data were collected with a 53-item questionnaire about their social and demographic status, family, occupation, training, information-seeking behaviour, job satisfaction, hypnotic and tranquillizer drug use, tranquillizer and antidepressant prescriptions. The data were analysed using univariate and backward multiple logistic regressions. We found that GPs in Provence use hypnotics and tranquillizers at a significantly higher rate than the general population. We found significant associations with hypnotic and tranquillizer use only among the older group of GPs (older than 48 years). In this group, this drug use was related to the volume of services provided (billing sector), job dissatisfaction, lack of training, the 'family burden' and tranquillizer prescriptions. The strains associated with both medical practice and family burden have some influence on hypnotic and tranquillizer use among GPs; individual factors may influence prescribing attitudes and patient care as well.

Adult↗